1,168 research outputs found
Responsabilità del titolare del permesso di costruire, del committente, del costruttore e del direttore dei lavori, nonché anche del progettista per le opere subordinate a denuncia di inizio attività
No full textA new insight into the suggestion of a possible antigenic role of a member of the 70kD heat shock proteins.
No full text
Compendio di astronomia fisica : compilato sopra le opere del P. Angelo Secchi per uso delle scuole della Pontificia Università Gregoriana
No full textIntroduzione a: G. F. Cromaz Pagine goriziane. Liberal-nazionali e cattolici popolari italiani al Comune di Gorizia (1851-1914)
No full textThe author describes the activity of the communal administration in Gorizia from 1848 to 1918. He uses documents of the communal archive and of a former communal adviser, Luigi Faidutti, leader of christian-social party in the austrian Friuli. The essay gives an important place to discussion about the creation of a public water service
Rhétorique et compréhension
No full text@incollection{OL-FERRARI-2006, author = {St{é}phane Ferrari}, title = {{Rh{é}torique et compr{é}hension}}, chapter = {7}, pages = {195-224}, booktitle = {Compr{é}hension des langues et interaction}, editor = {G{é}rard Sabah}, series = {Trait{é} IC2, s{é}rie Cognition et traitement de l'information}, publisher = {Herm{è}s Sciences, Lavoisier}, year = {2006}
Introducing new tools for assessment of parent- and child-reported outcomes in paediatric rheumatology practice: a work in progress.
No full textCytokines in the management of high risk or advanced breast cancer: an update and expectation
No full textSome cytokines (interleukin (IL)-2, IL-11, transforming growth factor(TGF)beta) stimulate, while others (IL-12, IL-18, Interferons (IFNs)) inhibit breast cancer proliferation and/or invasion. So far IL-2, IFNalpha, IFNbeta and occasionally IFNgamma, IL-6, IL-12 have been used for the treatment of advanced breast cancer either to induce or increase hormone sensitivity and/or to stimulate cellular immunity. Only two long term pilot studies suggest that IL-2 and IFNbeta can improve clinical benefit and/or overall survival of metastatic breast cancer patients with minimal residual disease after chemotherapy or with disseminate disease non progressing during endocrine therapy. These results have been interpreted assuming that tumour microenvironment impairs the immune system of the host. Consequently, minimal disease or intense cytostatic effects following chemo or endocrine therapy, respectively, permit the patient's immune system to respond to the stimulatory effect of the cytokines. Therefore a prospective, phase III, randomised, simple blind trial has been planned. The aim is to assess whether the addition of IFNbeta and IL-2 to standard hormone therapy in postmenopausal patients with metastatic breast cancer and positive or unknown positive receptors prolongs the clinical benefit and survival since the metastatic diagnosis and the beginning of first line salvage antiestrogen therapy, compared with the results achieved with standard hormone therapy alone. If this immunotherapy prolongs survival of endocrine dependent metastatic breast cancer patients, IL-2 and IFNbeta can also be evaluated as adjuvant treatment of patients with positive estrogen receptors
Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients: a retrospective longitudinal study
No full textIn metastatic breast cancer tumour markers' increase predicts, by a few months (lead time) disease progression. In breast cancer patients with endocrine dependent metastatic disease, we reported a prolonged clinical benefit and overall survival when first line conventional antiestrogen hormone therapy was started at the lead time and also when an immunotherapy schedule was added to the same conventional hormone treatment. Thirty-two of these last patients were considered (group a). In 27 (group b) of these 32 patients who progressed during first line salvage hormone plus immunotherapy the lead time at the progression of metastatic disease during therapy was compared with that at the onset of metastases when the same patients were without treatment and with that of a control group (group c) who did not receive immunotherapy. At disease progression, CEA-TPA-CA15.3 sensitivity was 92.5% in the group b (studied patients) and 88.5% in the group c (controls). At the progression in the group b, CEA-TPA-CA15.3 lead time (m+/-sd, months) was significantly longer than in group c (12.1+/-12.9 vs 2.4+/-4.0) (P=0.000). Besides, in group b the lead time was significantly longer at the progression than at the metastatic onset (P=0.003) while in the group c the difference was near to significance (P=0.05). The CEA-TPA-CA15.3 tumour marker panel accurately predicted metastatic disease progression and immunotherapy significantly prolonged the CEA-TPA-CA15.3 lead time. This can be used for anticipating salvage treatment in these patient
- …
